Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • CCI seeks fresh...

    CCI seeks fresh application in Bayer-Monsanto deal

    Written by supriya kashyap kashyap Published On 2017-03-26T10:11:46+05:30  |  Updated On 26 March 2017 10:11 AM IST
    CCI seeks fresh application in Bayer-Monsanto deal

    New Delhi : The Competition Commission has asked for filing of fresh application with respect to German major Bayer AG's proposed USD 66 billion buyout of Monsanto.


    The deal, announced in September 2016, would create the world's biggest seed and pesticide firm.


    A source at the Competition Commission of India (CCI) said the regulator has asked for re-submission of application with regard to seeking approval for the Bayer-Monsanto deal.


    Specific reasons for seeking fresh application could not be immediately ascertained.


    CCI can ask for filing of fresh application in cases of mergers and acquisitions citing lack of adequate information and certain other ground.


    When contacted, a Bayer spokesperson said the process in India is going its regular course and "we are in dialogue with the Indian anti-trust authority in terms of the completeness of the data package".


    "We are unaware of any rejection of the application for approval of the agreed merger. Please understand that we are not commenting on further details," the spokesperson said in a statement.


    Mergers and acquisitions beyond a certain threshold require approval of the CCI.


    German chemical and pharma major Bayer and global biotech player Monsanto have presence in India, with the US firm selling genetically modified (GM) cotton seeds in the country for more than a decade.


    As per the earlier notice filed by Bayer before the CCI in October 2016, the "proposed combination raises no competitive concern in any of the overlap products".


    In India, both entities have presence in production and sale of vegetable seeds, cotton seeds as well as in production and sale of non-selective herbicides, according to that notice.


    After months of negotiations, Bayer and Monsanto in September last year announced signing of a definitive merger agreement. Under the deal, Bayer would acquire Monsanto for USD 128 per share in an all-cash transaction, which translates into an aggregate value of USD 66 billion.

    agreementBayerCompetition Commission of Indiagenetically modifiedMonsanto
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok